delivering environment. disruption Thank very the in to customers gaining Despite good our COVID-XX Thanks, team record related call. challenging XX and QX, everyone. a afternoon, new joining operations for revenue in and Rod, performed flawlessly, you our significant
of or the essential had the working. an from so reduced part home, our team For we workforce on-site members not either working or month quarter, last of
media and of our cell safety get with support biopreservation development media or stock products customers and pandemic. customers and and our the outreach orders the teams projects close more contact their running shipped research could history. Through during responded any replenishment our in Many other our therapy stayed and period We gene placed customer a in to BioLife's up proactive than continue all in unabated transition remotely. coronavirus to so
in While that therapy been it's for plans to considered and manufacturing began clear to affected gene cell to patients of well through trials our the their put years out. products gene inventory ago our which customers off-site storage have In hospital included that reallocation success we and are significantly place therapy thought business demonstrated media proved clinical order and workflow. the COVID volume planning their cell product are two continuity clearly by mission-critical retrospect, beds media
driver last growth growth sales that QX with were biopreservation growth QX. time revenue, in placed representing year. over new sequential first orders key last QX XX% XX% Turning revenue. was at We media $XX.X XX QX year We now over to $X.X and QX XXX% in quarter gained million, customers the growth in million year-over-year fourth XXXX. and of over XX% the sequential which finished Biopreservation media
Cellphire, Some Trevira Sanofi, Genibet, notable new include accounts and PACT Vascugen Ventria. Pharma
a also been or to vaccines media pleased cell-based of we're used processed you biopreservation products working have on customer request of media products to in in XXX our additional gene I'm for proprietary cross-reference several supplying use CryoStor also that file cell tell over U.S. that estimate or clinical the master We We for human XX treatments COVID-XX. HypoThermosol customers therapies. clinical trials FDA applications. and
product new biologics. at frozen Turning first ThawSTAR shipped line quarter material revenue of $XXX,XXX. new QX products in with cryo to batch bags. we biologic is to automated safely an the of thawing on expectation in update our automate This the first In designed thawing our line water-free of under our frozen just ThawSTAR the CB was product. for
AC and including six We customers Notch Therapies, gained Therapeutics ThawSTAR Honeycomb Biotechnologies. new also Alvotech,
to With and cloud XX therapy courier our in evo continue evo.is cold customers the traction chain new management platform our gain gene QX. including and space containers with smart cell partners we app shipping adding in the
serving We and supporting platform med largest gene nearly are of our our through therapy with specialty space. XXX relationships clinical now cell trials, evo the two with regen carriers the
and evo, to in the we a information to remained revenue but existing has validations to support the ramps as shipping seeing in up, existing we're cell delays in resulting this completing at evo QX impacted activity companies. emerge While inbound systems that gene and containers are use leading product use. $XXX,XXX non-optimized by in by platform confident customer interest transition are increased therapy will as This been modest COVID-XX competitor strong and continuing
cash as On large capital delayed have CBS $X.X revenue of equipment, could in revenue pandemic. several purchases during we our the management QX customers last and to also the therapy products. stream, product many and but million the cell included plan, Biogenic some companies shipments Systems whom of our our quarter. revenue Custom chain a cold or due use product to CBS booked thaw gene COVID This conservation leading was below plans line, of slightly the media,
NexImmune. being customers and new accounts CBS eight two We freezer Lacerta with Therapeutics gained notable
and Precision, Fujifilm, Astellas, more leading For therapy Scientific, and than Mayo, includes of Juno, many Lonza, XXX Fisher Orchard, freezer Norwest, such Celgene, companies, cell and base Sorrento. Glaxo, Bellicum, the totals Hitachi, customer accounts as KITE, Fate, perspective, our pharma Biosigma developers gene now and AbbVie,
to of cold total patent applications our our were I'd like new to technologies. property XX with three on pending update in additional now and review related patents management to This XX first the quarter patents issued brings we chain our intellectual of the granted submitted process. an give estate. XXXX In
high-value I'll announced Casdin We're enables to I Capital acquisitions, of to licensing and and growth the new through cell we external shareholder tools by of the portfolio a significantly call provide Before investment that assets targeting us expand have over growth services to we equity in balance grow partner therapy and Rod, some our of years. fortunate bioproduction existing on aggressively business the a our We co-investments Casdin strategy that have market. gene sheet few comments internal to turn over next capital believe back today a combination the Capital. our to strengthen innovation,
financial We're or committed targets co-investments space playing may consolidating the bioproduction acquisitions lead jointly anticipate Casdin to to with to and a identify role that tool in continuing additional supplier their support. outright with
pass present the financials I'll Rod to call QX. Rod? over our Now for back to
